Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

ConditionITP - Immune Thrombocytopenia

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-75

SponsorSohag University

About this trial

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

Eltrombopag
Drug
ITP patients will receive Eltrombopag and evulate occurance of liver disordres .

Treatment groups

100 Participants

are divided into 1 treatment group

Group A: this group will receive Eltrombopag tabeltsExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

•To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

the incidence and severity of liver dysfunction in ITP patients

Time frame

3-6 months after receiving eltombopag

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sohag University

Lead sponsor

Source ClinicalTrials.gov

Apply now